FoodNavigator4h
Outcry as Novo Nordisk Foundation looks at UPF classification
It stressed that while the funding came from the Novo Nordisk Foundation, the project itself would be carried out by ...
FINAL NVO DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Novo Nordisk A/S Investors to Join the Class Action Lawsuit
NEW YORK, NY / ACCESS Newswire / March 24, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, ...
The Motley Fool14d
Why Novo Nordisk Stock Is Falling Today
Novo Nordisk announced that its next-generation weight-loss drug CagriSema helped obese or overweight adult patients with type 2 diabetes lose 15.7% of their weight in a recent trial. That figure ...
Novo bets on 'triple G' obesity drug in up to $2 billion deal with Chinese biotech
By Mariam Sunny (Reuters) -Danish drugmaker Novo Nordisk has bought global rights to China-based United Laboratories International's so-called "triple-G" weight-loss drug candidate in a deal worth up ...
Novo Nordisk Strikes $2B Deal for Obesity Drug
KEY TAKEAWAYS Novo Nordisk has signed an exclusive global licensing deal worth up to $2 billion for UBT251, a weight-loss ...
Newsable Asianet News on MSN1h
Novo Nordisk Signs $2B Deal For Obesity Drug With Chinese Biotech: Retail Sentiment Improves
Drugmaker Novo Nordisk A/S (NVO) on Monday entered into an exclusive license agreement worth up to $2 billion with ...
MT Newswires on MSN5h
Novo Nordisk Strikes Up to $2 Billion Licensing Deal for Chinese Firm's Obesity, Diabetes Drug Candidate
Novo Nordisk (NVO) secured exclusive global rights to United Laboratories International's therapeutic candidate for obesity and type 2 diabetes in a licensing deal worth up to $2 billion. The product ...